MXCT
NASDAQMaxCyte Inc.
Price$1.13-0.03 (-2.16%)
01:30 PM07:45 PM
News · 26 weeks25-83%
2025-12-212026-06-14
Mix2190d
- SEC Filings10(48%)
- Insider5(24%)
- Earnings3(14%)
- Other2(10%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form 8-K filed by MaxCyte Inc.8-K - MAXCYTE, INC. (0001287098) (Filer)
- SECSEC Form 10-Q filed by MaxCyte Inc.10-Q - MAXCYTE, INC. (0001287098) (Filer)
- SECMaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MAXCYTE, INC. (0001287098) (Filer)
- PRMaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 GuidanceFirst quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million MaxCyte's Board authorized a $10 million share repurchase program ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results an
- SECSEC Form DEFA14A filed by MaxCyte Inc.DEFA14A - MAXCYTE, INC. (0001287098) (Filer)
- SECSEC Form DEF 14A filed by MaxCyte Inc.DEF 14A - MAXCYTE, INC. (0001287098) (Filer)
- PRMaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and ar
- INSIDERSEC Form 4 filed by Ahuja Parmeet4 - MAXCYTE, INC. (0001287098) (Issuer)
- SECSEC Form S-8 filed by MaxCyte Inc.S-8 - MAXCYTE, INC. (0001287098) (Filer)
- INSIDERSEC Form 4 filed by Ahuja Parmeet4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ahuja Parmeet3 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERSEC Form 4 filed by Masoud Maher4 - MAXCYTE, INC. (0001287098) (Issuer)
- PRMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 375,000 shares of MaxCyte's common stock and a service-based restricted stock unit ("RSU") award with respect to 187,500 shares of MaxCyte's common stock to Parmeet Ahuja in connection with his appointment as Chief Financial Officer of MaxCyte. The awards were granted unde
- SECMaxCyte Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - MAXCYTE, INC. (0001287098) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MaxCyte Inc.SCHEDULE 13G/A - MAXCYTE, INC. (0001287098) (Subject)
- SECSEC Form 10-K filed by MaxCyte Inc.10-K - MAXCYTE, INC. (0001287098) (Filer)
- SECMaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MAXCYTE, INC. (0001287098) (Filer)
- PRMaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 GuidanceFourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md., March 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform
- PRMaxCyte Appoints Parmeet Ahuja as Chief Financial OfficerROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. "Parmeet is an exceptionally talented finance leader whose experience and expertise position him well to strengthen MaxCyte's financial operations," said Maher Masoud, Chief Executive Officer. "His deep background in
- SECSEC Form 8-K filed by MaxCyte Inc.8-K - MAXCYTE, INC. (0001287098) (Filer)
- INSIDERSEC Form 4 filed by Swirsky Douglas J4 - MAXCYTE, INC. (0001287098) (Issuer)
- PRMaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discoveryROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of ExPERT DTx™, a new high throughput transfection platform for research and drug discovery applications. This modular, 96-well electroporation system enables labs to transfect primary cells and cell lines with minimal cellular stress, helping researchers to uncover valuable insights and better understand fundamental biological processes before scaling up to larger transfection volumes. ExPERT DTx stream
- PRMaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advanc
- SECMaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - MAXCYTE, INC. (0001287098) (Filer)
- PRMaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial ResultsROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Fourth Quarter and Full Year 2025 Results Core revenue in the fourth quarter is expected to be between $6.6 million and $6.7 million.Core revenue for the full year is expected to be between $29.5 million and $29.6 million.Strategic Platform License (SPL) program-related revenue i
MXCT FAQ
7 questionsWhat does MaxCyte Inc. do?
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and...Where does MXCT stock trade?
MaxCyte Inc. (MXCT) is listed on NASDAQ.What sector and industry is MXCT in?
MaxCyte Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did MaxCyte Inc. go public?
MaxCyte Inc. (MXCT) completed its IPO in 2021.What are analysts saying about MXCT?
MaxCyte Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2025-08-11.What companies are similar to MXCT?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc). Compare MXCT side-by-side with any of them on Quantisnow.How can I track MXCT on Quantisnow?
Quantisnow aggregates MaxCyte Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MXCT to receive live email and push alerts on every new disclosure.